Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine(PNEU-PLAN)

Despite widespread use of pneumococcal conjugate vaccines (PCVs) in children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In addition, many children do not complete their PCV course on schedule. V114 is a 15-valent PCV that contains two epidemiologically important serotypes, 22F and 33F, in addition to the 13 serotypes present in PCV13, the licensed 13-valent PCV.

Research

Examining the entire delayed respiratory syncytial virus season in Western Australia

An interseasonal resurgence of respiratory syncytial virus (RSV) was observed in Western Australia at the end of 2020. Our previous report describing this resurgence compared the 2019 and 2020 calendar years, capturing only part of the 2020/21 season.

About

Learn more about the Wesfarmers Centre of Vaccines and Infectious Diseases

Current studies

To improve the health of the community through immunisation and prevention of infectious diseases, we are conducting clinical trials of vaccines.

CHIP Study

The CHIP Study investigates how burn injuries in children affect their immune system.

Allergy Prevention

Allergies have been on the rise in Australia over the past 20 years, with three out of every 10 babies born each year now developing a food-related

COVID-19

The year 2020 has been marked by possibly the greatest health challenge to face modern society. The emergence of COVID-19 as a novel human pathogen

Upcoming Studies 2021

Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au The Vaccine Trials Group

Māori and Pacific governance

Māori and Pacific governance groups discuss and inform study protocols and issues that have arisen during the study, particularly those pertaining to Māori and Pacific ARF patients and their whānau.